Pancreatic Cancer

P1/2, N=71, Recruiting, Onconic Therapeutics Inc. | Phase classification: P1 --> P1/2 | N=30 --> 71 | Trial completion date: Jun 2026 --> Apr 2030 | Trial primary completion date: Mar 2026 --> Apr 2030

P=N/A, N=200, Recruiting, Nuvance Health | Trial completion date: Nov 2026 --> Nov 2030 | Trial primary completion date: Nov 2026 --> Nov 2030

P=N/A, N=0, Withdrawn, Thomas Jefferson University | N=376 --> 0 | Terminated --> Withdrawn

The spatial colocalization of BIRC3 with tumor vasculature in invasive carcinoma tissue suggests a novel interaction. Our discoveries using an integrated single-cell and spatial transcriptomic approach reveal a high-resolution molecular map of prostate cancer with spatial features that may provide further therapeutic investigation.

Functionally, SIRT7 inhibition enhanced radiation-induced DNA damage and apoptosis in a partially MEN1-dependent manner and significantly suppressed tumor growth in patient-derived organoids and multiple independent xenograft models. Collectively, these findings define a catalytic activity-dependent SIRT7-DNMT1-MEN1 epigenetic axis that modulates DDR and radiosensitivity, supporting SIRT7 targeting as a strategy to improve radiotherapy efficacy in PanNETs.

Hypoxia-inducible factor-1α (HIF-1α) expression was used to evaluate PDAC hypoxia levels, and patients were stratified into low and high hypoxia groups...High-hypoxia tumors were associated with poorer differentiation (P<0.001). T2* mapping may serve as a noninvasive imaging biomarker for stratifying the hypoxic microenvironment in PDAC.

An online calculator was developed to facilitate individualized risk assessment. This model may support preoperative decision-making and reduce non-beneficial resections in NAT-treated PDAC patients.

These results suggest that combining molecular fingerprints with AI can effectively model PK properties. This approach supports the use of AI for accelerating drug repurposing, especially for disease conditions.

Similarly, ACADVL expression was significantly elevated in the DP group compared with the DM group (p < 0.01) and healthy controls (p < 0.0001). The survival analysis also suggests that high ACADVL expression is a favorable prognostic biomarker.

Therefore, when creating animal models with xenografted tumors, it is important to understand the angiogenic potential of cancer cells, especially for studying drug candidates with an antiangiogenic effect. Also, the combination of optoacoustics and immunohistochemical analysis with FLIM imaging allows for a comprehensive assessment of both vascularization and the metabolic state of the tumor, which can help predict the therapeutic response.

These findings underscore the importance of combination therapeutic approaches in overcoming resistance. This review summarizes current evidence on the mechanisms of action, resistance pathways, and potential combination strategies of MRTX1133 in digestive system cancers, and discusses its translational relevance and clinical implications for KRAS G12D mutant malignancies.

FOLH1 may be involved in tumor progression by regulating amino acid metabolic pathways and the immune microenvironment. It is a promising pan-cancer prognostic marker and synergistic target for immunotherapy.